We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Nia6.0
Niacinamide Research
Mostly mechanism / observationalHigh safety
7 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Niacinamide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 1995–2022 with a typical study size of 50 participants.
Based on 7 studies · 5 RCTs · 301 total participants
Confidence
Moderate
By outcome
Skin healthAntibiotic-free reduction in inflammatory acne lesions (comparable to clindamycin in one trial) · 8 weeks · Improved barrier function (lower TEWL) and reduced sallowness/red blotchiness (cosmetic) · 4-12 weeks · Modest reduction in fine lines from one industry split-face trial (cosmetic; the thinnest part of the evidence) · 8-12 weeks
Mostly mechanism / observational4 studies
Skin tone & pigmentationModest reduction in hyperpigmentation and improved skin lightness/clarity (cosmetic, not a health outcome) · 4-12 weeks
Mostly mechanism / observational3 studies
Safety profile
Too few graded studies2 studies
Steady research
1 study in the last 5 years
199520082022
1RCTn=50 · small study2005
Analyses of the data revealed a variety of significant skin appearance improvement effects for topical niacinamide: reductions in fine lines and wrinkles, hyperpigmented spots, red blotchiness, and skin sallowness (yellowing).
Bissett DL, Oblong JE, Berge CA. · Dermatol Surg (2005)
Double-blind, left-right randomized split-face design: 5% niacinamide vs vehicle applied twice daily for 12 weeks in 50 white women with facial photoaging
Significant improvements vs vehicle in fine lines/wrinkles, hyperpigmented spots, red blotchiness, and yellowing (sallowness)
Elasticity improved by cutometry; well tolerated. Foundational facial-aging cosmetic trial (Procter & Gamble)
In the clinical studies, niacinamide significantly decreased hyperpigmentation and increased skin lightness compared with vehicle alone after 4 weeks of use.
Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE. · Br J Dermatol (2002)
Paired clinical trial: 18 subjects with hyperpigmentation used 5% niacinamide vs vehicle moisturizer (plus a separate facial-tanning arm)
5% niacinamide significantly reduced hyperpigmentation and increased skin lightness vs vehicle by 4 weeks
Mechanistically, niacinamide gave 35-68% inhibition of melanosome transfer in coculture but had no effect on tyrosinase or melanocyte melanogenesis
Split-face RCT in 27 melasma patients: 4% niacinamide vs 4% hydroquinone (HQ) for 8 weeks, both with sunscreen
Both sides improved with no significant colorimetric difference, but good-to-excellent response was lower with niacinamide (44%) than HQ (55%)
Niacinamide had fewer side effects (18% vs 29% with HQ) and reduced mast-cell infiltrate and solar elastosis histologically — the key counter-evidence positioning it as a better-tolerated but slightly weaker alternative
After 8 weeks, both treatments produced comparable (P = 0.19) beneficial results in the Physician's Global Evaluation of Inflammatory Acne; 82% of the patients treated with nicotinamide gel and 68% treated with clindamycin gel were improved.
Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DK. · Int J Dermatol (1995)
Double-blind RCT: 76 patients with moderate inflammatory acne randomized to 4% nicotinamide gel (n=38) vs 1% clindamycin gel (n=38), twice daily for 8 weeks
Comparable global improvement (82% nicotinamide vs 68% clindamycin, P=0.19) with no significant difference
Supports topical niacinamide as an antibiotic-free acne option of comparable efficacy to clindamycin
Evidence has shown ascorbic acid, azelaic acid, glycolic acid, kojic acid, salicylic acid, and niacinamide to be effective as adjuvant therapies with minimal side effects.
González-Molina V, Martí-Pineda A, González N. · J Clin Aesthet Dermatol (2022)
PRISMA systematic review of topical melasma agents: 348 studies screened, 80 met inclusion criteria
Niacinamide is classified as an effective adjuvant therapy with minimal side effects
Triple-combination therapy and hydroquinone remain the strongest-evidence, gold-standard treatments — niacinamide is positioned as adjuvant, not first-line; reviewers note small samples and a lack of large, long-term trials
6RCTn=130 · medium study2006
The 2% niacinamide treated group demonstrated significantly lowered SER after 2 and 4 weeks of application.
Draelos ZD, Matsubara A, Smiles K. · J Cosmet Laser Ther (2006)
Two trials: a double-blind placebo-controlled study in 100 Japanese subjects (4 weeks) and a 30-subject Caucasian split-face study (6 weeks)
In Japanese subjects, 2% niacinamide significantly lowered sebum excretion rate (SER) at 2 and 4 weeks vs placebo
In Caucasian subjects, casual sebum levels fell but SER did not — the effect was population/measure dependent and modest
Topical application of nicotinamide increased ceramide and free fatty acid levels in the stratum corneum, and decreased transepidermal water loss in dry skin.
Tanno O, Ota Y, Kitamura N, Katsube T, Inoue S. · Br J Dermatol (2000)
In cultured human keratinocytes, nicotinamide increased ceramide biosynthesis 4.1-5.5-fold and other barrier lipids, via upregulation of serine palmitoyltransferase
Topical application in vivo increased stratum-corneum ceramide and free fatty acid and decreased transepidermal water loss (TEWL) in dry skin
Foundational mechanism for niacinamide's barrier / anti-TEWL effect (in-vitro plus a small in-vivo component)